Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Stephen D. Wiviott, M.D., Eugene Braunwald, M.D., Carolyn H. McCabe, B.S., Gilles Montalescot, M.D., Ph.D., Witold Ruzyllo, M.D., Shmuel Gottlieb, M.D., Franz-Joseph Neumann, M.D., Diego Ardissino, M.D., Stefano De Servi, M.D., Sabina A. Murphy, M.P.H., Jeffrey Riesmeyer, M.D., Govinda Weerakkody, Ph.D., C. Michael Gibson, M.D., Elliott M. Antman, M.D., for the TRITON–TIMI 38 Investigators
Background Dual-antiplatelet therapy with aspirin and a thienopyridineis a cornerstone of treatment to prevent thrombotic complicationsof acute coronary syndromes and percutaneous coronary intervention.
Methods To compare prasugrel, a new thienopyridine, with clopidogrel,we randomly assigned 13,608 patients with moderate-to-high-riskacute coronary syndromes with scheduled percutaneous coronaryintervention to receive prasugrel (a 60-mg loading dose anda 10-mg daily maintenance dose) or clopidogrel (a 300-mg loadingdose and a 75-mg daily maintenance dose), for 6 to 15 months.The primary efficacy end point was death from cardiovascularcauses, nonfatal myocardial infarction, or nonfatal stroke.The key safety end point was major bleeding.
Results The primary efficacy end point occurred in 12.1% ofpatients receiving clopidogrel and 9.9% of patients receivingprasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81;95% confidence interval [CI], 0.73 to 0.90; P<0.001). Wealso found significant reductions in the prasugrel group inthe rates of myocardial infarction (9.7% for clopidogrel vs.7.4% for prasugrel; P<0.001), urgent target-vessel revascularization(3.7% vs. 2.5%; P<0.001), and stent thrombosis (2.4% vs.1.1%; P<0.001). Major bleeding was observed in 2.4% of patientsreceiving prasugrel and in 1.8% of patients receiving clopidogrel(hazard ratio, 1.32; 95% CI, 1.03 to 1.68; P=0.03). Also greaterin the prasugrel group was the rate of life-threatening bleeding(1.4% vs. 0.9%; P=0.01), including nonfatal bleeding (1.1% vs.0.9%; hazard ratio, 1.25; P=0.23) and fatal bleeding (0.4% vs.0.1%; P=0.002).
Conclusions In patients with acute coronary syndromes with scheduledpercutaneous coronary intervention, prasugrel therapy was associatedwith significantly reduced rates of ischemic events, includingstent thrombosis, but with an increased risk of major bleeding,including fatal bleeding. Overall mortality did not differ significantlybetween treatment groups. (ClinicalTrials.gov number, NCT00097591
[ClinicalTrials.gov]
.)
Source Information
From Brigham and Women's Hospital and Harvard Medical School, Boston (S.D.W., E.B., C.H.M., S.A.M., C.M.G., E.M.A.); Institut de Cardiologie and INSERM Unit 856, Pitié–Salpêtrière University Hospital, Paris (G.M.); Instytut Kardiologii, Warsaw, Poland (W.R.); Bikur Cholim Hospital, Jerusalem, Israel (S.G.); Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany (F.-J.N.); Azienda Ospedaliero–Universitaria di Parma, Parma, Italy (D.A.); Azienda Ospedaliera Civile di Legano, Legano, Italy (S.D.S.); and Eli Lilly Research Laboratories, Indianapolis (J.R., G.W.). This article (10.1056/NEJMoa0706482) was published at www.nejm.org on November 4, 2007.
Address reprint requests to Dr. Antman at the Cardiovascular Division, Brigham and Women's Hospital, TIMI Study Group, 350 Longwood Ave., 1st Fl., Boston, MA 02115, or at eantman{at}rics.bwh.harvard.edu.
Prasugrel versus Clopidogrel
Serebruany V., Pasceri V., Patti G., Di Sciascio G., von Lewinski F., Riggert J., Paulus W., Wiviott S. D., Braunwald E., Antman E. M., Bhatt D. L.
Extract |
Full Text |
PDF
N Engl J Med 2008;
358:1298-1301, Mar 20, 2008.
Correspondence
This article has been cited by other articles:
Lamas, G. A., Escolar, E., Faxon, D. P.
(2010). Review Article: Examining Treatment of ST-Elevation Myocardial Infarction: The Importance of Early Intervention. J CARDIOVASC PHARMACOL THER
15: 6-16
[Abstract]
Kaul, S., Diamond, G. A.
(2010). Trial and Error: How to Avoid Commonly Encountered Limitations of Published Clinical Trials. J Am Coll Cardiol
55: 415-427
[Abstract][Full Text]
Gurbel, P. A., Tantry, U. S.
(2010). Combination Antithrombotic Therapies. Circulation
121: 569-583
[Full Text]
BHATT, D. L.
(2010). Controversies in non-ST-elevation acute coronary syndromes and percutaneous coronary interventions. Cleveland Clinic Journal of Medicine
77: 101-109
[Abstract][Full Text]
Rocca, B., Petrucci, G.
(2010). Personalized Medicine, Pharmacogenetics, and Clopidogrel: Unraveling Variability of Response. Mol. Interv.
10: 12-19
[Full Text]
Farid, N. A., Kurihara, A., Wrighton, S. A.
(2010). Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans. J Clin Pharmacol
50: 126-142
[Abstract][Full Text]
Simoons, M. L., Windecker, S.
(2010). Controversies in Cardiovascular Medicine Chronic stable coronary artery disease: drugs vs. revascularization. Eur Heart J
: ehp605v1-ehp605
[Abstract][Full Text]
Pinto, D. S.
(2010). A 43-Year-Old Man With Angina, Elevated Troponin, and Lateral ST Depression: Management of Acute Coronary Syndromes. JAMA
303: 54-63
[Abstract][Full Text]
Cattaneo, M.
(2010). New P2Y12 Inhibitors. Circulation
121: 171-179
[Full Text]
Van de Werf, F.
(2010). Balancing Benefit and Bleeding Risk of Antithrombotic Agents in the Individual Patient With an Acute Coronary Syndrome. Circulation
121: 5-7
[Full Text]
Pocock, S. J., Mehran, R., Clayton, T. C., Nikolsky, E., Parise, H., Fahy, M., Lansky, A. J., Bertrand, M. E., Lincoff, A. M., Moses, J. W., Ohman, E. M., White, H. D., Stone, G. W.
(2010). Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications: Assessment From the Acute Catheterization and Urgent Intervention Triage Strategy Trial. Circulation
121: 43-51
[Abstract][Full Text]
Mahoney, E. M., Wang, K., Arnold, S. V., Proskorovsky, I., Wiviott, S., Antman, E., Braunwald, E., Cohen, D. J.
(2010). Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation
121: 71-79
[Abstract][Full Text]
Serebruany, V., Rao, S. V., Silva, M. A., Donovan, J. L., Kannan, A. O., Makarov, L., Goto, S., Atar, D.
(2010). Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J
31: 227-235
[Abstract][Full Text]
Angiolillo, D. J., Capodanno, D., Goto, S.
(2010). Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J
31: 17-28
[Abstract][Full Text]
Frelinger, A. L. III, Li, Y., Linden, M. D., Barnard, M. R., Fox, M. L., Christie, D. J., Furman, M. I., Michelson, A. D.
(2009). Association of Cyclooxygenase-1-Dependent and -Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterization. Circulation
120: 2586-2596
[Abstract][Full Text]
Serebruany, V. L., Atar, D.
(2009). The PLATO trial: do you believe in magic?. Eur Heart J
0: ehp545v2-ehp545
[Full Text]
Tomoda, H., Rosenstein, R. S., Parra, D., Cattaneo, M., Wartak, S. A., Lotfi, A., Rothberg, M., Wallentin, L., Emanuelsson, H., Harrington, R. A.
(2009). Ticagrelor versus clopidogrel in acute coronary syndromes.. NEJM
361: 2385-2386
[Full Text]
Kastrati, A., Ndrepepa, G.
(2009). Cangrelor -- A Champion Lost in Translation?. NEJM
361: 2382-2384
[Full Text]
Harrington, R. A., Stone, G. W., McNulty, S., White, H. D., Lincoff, A. M., Gibson, C. M., Pollack, C. V. Jr., Montalescot, G., Mahaffey, K. W., Kleiman, N. S., Goodman, S. G., Amine, M., Angiolillo, D. J., Becker, R. C., Chew, D. P., French, W. J., Leisch, F., Parikh, K. H., Skerjanec, S., Bhatt, D. L.
(2009). Platelet Inhibition with Cangrelor in Patients Undergoing PCI. NEJM
361: 2318-2329
[Abstract][Full Text]
Bhatt, D. L., Lincoff, A. M., Gibson, C. M., Stone, G. W., McNulty, S., Montalescot, G., Kleiman, N. S., Goodman, S. G., White, H. D., Mahaffey, K. W., Pollack, C. V. Jr., Manoukian, S. V., Widimsky, P., Chew, D. P., Cura, F., Manukov, I., Tousek, F., Jafar, M. Z., Arneja, J., Skerjanec, S., Harrington, R. A., the CHAMPION PLATFORM Investigators,
(2009). Intravenous Platelet Blockade with Cangrelor during PCI. NEJM
361: 2330-2341
[Abstract][Full Text]
Fox, K. A.A., Carruthers, K., Steg, Ph. G., Avezum, A., Granger, C. B., Montalescot, G., Goodman, S. G., Gore, J. M., Quill, A. L., Eagle, K. A., for the GRACE Investigators,
(2009). Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events. Eur Heart J
0: ehp499v1-ehp499
[Abstract][Full Text]
LAZAR, L. D., LINCOFF, A. M.
(2009). Prasugrel for acute coronary syndromes: Faster, more potent, but higher bleeding risk. Cleveland Clinic Journal of Medicine
76: 707-714
[Abstract][Full Text]
Fauler, J.
(2009). Clinical pharmacology of antithrombotic drugs in coronary artery disease. Ther Adv Cardiovasc Dis
3: 465-478
[Abstract]
Kushner, F. G., Hand, M., Smith, S. C. Jr, King, S. B. III, Anderson, J. L., Antman, E. M., Bailey, S. R., Bates, E. R., Blankenship, J. C., Casey, D. E. Jr, Green, L. A., Hochman, J. S., Jacobs, A. K., Krumholz, H. M., Morrison, D. A., Ornato, J. P., Pearle, D. L., Peterson, E. D., Sloan, M. A., Whitlow, P. L., Williams, D. O.
(2009). 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol
54: 2205-2241
[Full Text]
Kandzari, D. E., Angiolillo, D. J., Price, M. J., Teirstein, P. S.
(2009). Identifying the "Optimal" Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Revascularization. J Am Coll Cardiol Intv
2: 1279-1285
[Abstract][Full Text]
Seet, R. C.-S., Chen, C. P.L.
(2009). Optimizing Antiplatelet Therapy in High-Risk Patients With Atrial Fibrillation: Insights From Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A). Stroke
40: 3883-3885
[Full Text]
Lopez-Sendon, J. L., Storey, R. F.
(2009). Introduction. Eur Heart J Suppl
11: G2-G3
[Full Text]
Cattaneo, M.
(2009). Fast, potent, and reliable inhibition of platelet aggregation. Eur Heart J Suppl
11: G9-G13
[Abstract][Full Text]
Neumann, F.-J.
(2009). Balancing efficacy and safety in the TRITON-TIMI 38 trial. Eur Heart J Suppl
11: G14-G17
[Abstract][Full Text]
Montalescot, G.
(2009). Benefits for specific subpopulations in TRITON-TIMI 38. Eur Heart J Suppl
11: G18-G24
[Abstract][Full Text]
Lopez-Sendon, J. L., Storey, R. F.
(2009). Conclusions. Eur Heart J Suppl
11: G25-G26
[Full Text]
Kushner, F. G., Hand, M., Smith, S. C. Jr, King, S. B. III, Anderson, J. L., Antman, E. M., Bailey, S. R., Bates, E. R., Blankenship, J. C., Casey, D. E. Jr, Green, L. A., Hochman, J. S., Jacobs, A. K., Krumholz, H. M., Morrison, D. A., Ornato, J. P., Pearle, D. L., Peterson, E. D., Sloan, M. A., Whitlow, P. L., Williams, D. O.
(2009). 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation
120: 2271-2306
[Full Text]
Faxon, D. P.
(2009). Women are like men ... Sometimes.. J Am Coll Cardiol
54: 1946-1948
[Full Text]
Schulz, S., Schuster, T., Mehilli, J., Byrne, R. A., Ellert, J., Massberg, S., Goedel, J., Bruskina, O., Ulm, K., Schomig, A., Kastrati, A.
(2009). Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J
30: 2714-2721
[Abstract][Full Text]
RAYMOND, C., MENON, V.
(2009). Dual antiplatelet therapy in coronary artery disease: A case-based approach. Cleveland Clinic Journal of Medicine
76: 663-670
[Abstract][Full Text]
Hagihara, K., Kazui, M., Kurihara, A., Yoshiike, M., Honda, K., Okazaki, O., Farid, N. A., Ikeda, T.
(2009). A Possible Mechanism for the Differences in Efficiency and Variability of Active Metabolite Formation from Thienopyridine Antiplatelet Agents, Prasugrel and Clopidogrel. Drug Metab. Dispos.
37: 2145-2152
[Abstract][Full Text]
White, H. D.
(2009). Is there an acceptable ceiling for bleeding for an antithrombotic drug dose to be tested in a phase 3 trial?. Eur Heart J
30: 2556-2557
[Full Text]
Lindsey, J. B., Marso, S. P., Pencina, M., Stolker, J. M., Kennedy, K. F., Rihal, C., Barsness, G., Piana, R. N., Goldberg, S. L., Cutlip, D. E., Kleiman, N. S., Cohen, D. J., on behalf of the EVENT Registry Investigators,
(2009). Prognostic Impact of Periprocedural Bleeding and Myocardial Infarction After Percutaneous Coronary Intervention in Unselected Patients: Results From the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. J Am Coll Cardiol Intv
2: 1074-1082
[Abstract][Full Text]
Gladding, P., White, H., Voss, J., Ormiston, J., Stewart, J., Ruygrok, P., Bvaldivia, B., Baak, R., White, C., Webster, M.
(2009). Pharmacogenetic Testing for Clopidogrel Using the Rapid INFINITI Analyzer: A Dose-Escalation Study. J Am Coll Cardiol Intv
2: 1095-1101
[Abstract][Full Text]
Gurbel, P. A., Tantry, U. S., Shuldiner, A. R.
(2009). The Worry About Clopidogrel "Nonresponsiveness": Identification and Treatment in the Post-Percutaneous Coronary Intervention Patient. J Am Coll Cardiol Intv
2: 1102-1104
[Full Text]
Simon, D. I., Parikh, S. A.
(2009). Hunting for the "Sweet Spot" in P2Y12 Receptor Blockade. J Am Coll Cardiol
54: 1447-1449
[Full Text]
Kumar, A., Cannon, C. P.
(2009). Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clin Proc.
84: 917-938
[Abstract][Full Text]
Marin, F., Gonzalez-Conejero, R., Capranzano, P., Bass, T. A., Roldan, V., Angiolillo, D. J.
(2009). Pharmacogenetics in cardiovascular antithrombotic therapy.. J Am Coll Cardiol
54: 1041-1057
[Abstract][Full Text]
Schomig, A.
(2009). Ticagrelor -- Is There Need for a New Player in the Antiplatelet-Therapy Field?. NEJM
361: 1108-1111
[Full Text]
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., Mahaffey, K. W., Scirica, B. M., Skene, A., Steg, P. G., Storey, R. F., Harrington, R. A., the PLATO Investigators,
(2009). Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. NEJM
361: 1045-1057
[Abstract][Full Text]
Bonaca, M. P., Steg, P. G., Feldman, L. J., Canales, J. F., Ferguson, J. J., Wallentin, L., Califf, R. M., Harrington, R. A., Giugliano, R. P.
(2009). Antithrombotics in acute coronary syndromes.. J Am Coll Cardiol
54: 969-984
[Abstract][Full Text]
Unger, E. F.
(2009). Weighing Benefits and Risks -- The FDA's Review of Prasugrel. NEJM
361: 942-945
[Full Text]
Bhatt, D. L.
(2009). Prasugrel in Clinical Practice. NEJM
361: 940-942
[Full Text]
Collet, J.-P., Montalescot, G.
(2009). Review: Platelet Function Testing and Implications for Clinical Practice. J CARDIOVASC PHARMACOL THER
14: 157-169
[Abstract]
Wykrzykowska, J. J., Serruys, P. W., Onuma, Y., de Vries, T., van Es, G.-A., Buszman, P., Linke, A., Ischinger, T., Klauss, V., Corti, R., Eberli, F., Wijns, W., Morice, M.-C., di Mario, C., van Geuns, R. J., Juni, P., Windecker, S.
(2009). Impact of Vessel Size on Angiographic and Clinical Outcomes of Revascularization With Biolimus-Eluting Stent With Biodegradable Polymer and Sirolimus-Eluting Stent With Durable Polymer: The LEADERS Trial Substudy. J Am Coll Cardiol Intv
2: 861-870
[Abstract][Full Text]
O'Donoghue, M., Antman, E. M., Braunwald, E., Murphy, S. A., Steg, P. G., Finkelstein, A., Penny, W. F., Fridrich, V., McCabe, C. H., Sabatine, M. S., Wiviott, S. D.
(2009). The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) Analysis.. J Am Coll Cardiol
54: 678-685
[Abstract][Full Text]
Wallentin, L.
(2009). P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J
30: 1964-1977
[Abstract][Full Text]
Ernest, C. S. II, Heathman, M. A., Wrishko, R. E.
(2009). Prediction of Prasugrel Active Metabolite Concentrations From 2 Downstream Inactive Metabolite Concentrations Using Multilinear Regression Analysis. J Clin Pharmacol
49: 973-983
[Abstract][Full Text]
Lasala, J. M., Cox, D. A., Dobies, D., Baran, K., Bachinsky, W. B., Rogers, E. W., Breall, J. A., Lewis, D. H., Song, A., Starzyk, R. M., Mascioli, S. R., Dawkins, K. D., Baim, D. S., for the ARRIVE 1 and ARRIVE 2 Participating Physic,
(2009). Drug-Eluting Stent Thrombosis in Routine Clinical Practice: Two-Year Outcomes and Predictors From the TAXUS ARRIVE Registries. Circ Cardiovasc Interv
2: 285-293
[Abstract][Full Text]
Bonello, L, De Labriolle, A, Scheinowitz, M, Lemesle, G, Roy, P, Steinberg, D H, Pinto Slottow, T L, Pakala, R, Pichard, A D, Barragan, P, Camoin-Jau, L, Dignat-George, F, Paganelli, F, Waksman, R
(2009). Emergence of the concept of platelet reactivity monitoring of response to thienopyridines. Heart
95: 1214-1219
[Abstract][Full Text]
Wrishko, R. E., Ernest, C. S. II, Small, D. S., Li, Y. G., Weerakkody, G. J., Riesmeyer, J. R., Macias, W. L., Rohatagi, S., Salazar, D. E., Antman, E. M., Wiviott, S. D., Braunwald, E., Ni, L.
(2009). Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON-TIMI 38. J Clin Pharmacol
49: 984-998
[Abstract][Full Text]
Braunwald, E.
(2009). Adventures in Cardiovascular Research. Circulation
120: 170-180
[Abstract][Full Text]
Holmes, D. R. Jr, Kereiakes, D. J., Kleiman, N. S., Moliterno, D. J., Patti, G., Grines, C. L.
(2009). Combining Antiplatelet and Anticoagulant Therapies.. J Am Coll Cardiol
54: 95-109
[Abstract][Full Text]
Michelson, A. D., Frelinger, A. L. III, Braunwald, E., Downey, W. E., Angiolillo, D. J., Xenopoulos, N. P., Jakubowski, J. A., Li, Y., Murphy, S. A., Qin, J., McCabe, C. H., Antman, E. M., Wiviott, S. D., for the TRITON-TIMI 38 Investigators,
(2009). Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J
30: 1753-1763
[Abstract][Full Text]
Van de Werf, F.
(2009). New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome?. Eur Heart J
30: 1695-1702
[Abstract][Full Text]
Wilson, J M
(2009). Diagnosis and treatment of acquired coronary artery disease in adults. Postgrad. Med. J.
85: 364-365
[Abstract][Full Text]
Rosenstein, R. S., Parra, D.
(2009). Letter by Rosenstein and Parra Regarding Article, "Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel: Thrombolysis in Myocardial Infarction 38". Circulation
119: e601-e601
[Full Text]
APPRAISE Steering Committee and Investigators,
(2009). Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial. Circulation
119: 2877-2885
[Abstract][Full Text]
Morrow, D. A., Wiviott, S. D., White, H. D., Nicolau, J. C., Bramucci, E., Murphy, S. A., Bonaca, M. P., Ruff, C. T., Scirica, B. M., McCabe, C. H., Antman, E. M., Braunwald, E.
(2009). Effect of the Novel Thienopyridine Prasugrel Compared With Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38: An Application of the Classification System From the Universal Definition of Myocardial Infarction. Circulation
119: 2758-2764
[Abstract][Full Text]
Kukreja, N., Onuma, Y., Garcia-Garcia, H. M., Daemen, J., van Domburg, R., Serruys, P. W., on behalf of the Interventional cardiologists of t,
(2009). The Risk of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Bare-Metal and Drug-Eluting Stents. J Am Coll Cardiol Intv
2: 534-541
[Abstract][Full Text]
Mehta, S. K., Frutkin, A. D., Lindsey, J. B., House, J. A., Spertus, J. A., Rao, S. V., Ou, F.-S., Roe, M. T., Peterson, E. D., Marso, S. P., on Behalf of the National Cardiovascular Data Regi,
(2009). Bleeding in Patients Undergoing Percutaneous Coronary Intervention: The Development of a Clinical Risk Algorithm From the National Cardiovascular Data Registry. Circ Cardiovasc Interv
2: 222-229
[Abstract][Full Text]
Prasad, A., Holmes, D. R
(2009). Update on dual antiplatelet therapy for percutaneous coronary intervention. Heart
95: 861-865
[Full Text]
Price, M. J.
(2009). Bedside Evaluation of Thienopyridine Antiplatelet Therapy. Circulation
119: 2625-2632
[Full Text]
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W. L., Braunwald, E., Sabatine, M. S.
(2009). Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes. Circulation
119: 2553-2560
[Abstract][Full Text]
Tousoulis, D., Briasoulis, A., Dhamrait, S. S, Antoniades, C., Stefanadis, C.
(2009). Effective platelet inhibition by aspirin and clopidogrel: where are we now?. Heart
95: 850-858
[Full Text]
Ford, N. F.
(2009). Clopidogrel Resistance: Pharmacokinetic or Pharmacogenetic?. J Clin Pharmacol
49: 506-512
[Abstract][Full Text]
Anderson, J. L.
(2009). Stopping the Hemorrhage: A New Baseline Bleeding Score Brings Us a Step Closer for Patients With Non-ST-Elevation Myocardial Infarction. Circulation
119: 1846-1849
[Full Text]
Subherwal, S., Bach, R. G., Chen, A. Y., Gage, B. F., Rao, S. V., Newby, L. K., Wang, T. Y., Gibler, W. B., Ohman, E. M., Roe, M. T., Pollack, C. V. Jr, Peterson, E. D., Alexander, K. P.
(2009). Baseline Risk of Major Bleeding in Non-ST-Segment-Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score. Circulation
119: 1873-1882
[Abstract][Full Text]
Palmerini, T., Marzocchi, A., Tamburino, C., Sheiban, I., Margheri, M., Vecchi, G., Sangiorgi, G., Santarelli, A., Bartorelli, A. L., Briguori, C., Vignali, L., Di Pede, F., Ramondo, A., Inglese, L., De Carlo, M., Bolognese, L., Benassi, A., Palmieri, C., Filippone, V., Sangiorgi, D., Barlocco, F., Lauria, G., De Servi, S.
(2009). Temporal pattern of ischemic events in relation to dual antiplatelet therapy in patients with unprotected left main coronary artery stenosis undergoing percutaneous coronary intervention.. J Am Coll Cardiol
53: 1176-1181
[Abstract][Full Text]
Jolly, S. S., Pogue, J., Haladyn, K., Peters, R. J.G., Fox, K. A.A., Avezum, A., Gersh, B. J., Rupprecht, H. J., Yusuf, S., Mehta, S. R.
(2009). Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J
30: 900-907
[Abstract][Full Text]
Fokkema, M. L., Vlaar, P. J., Svilaas, T., Vogelzang, M., Amo, D., Diercks, G. F.H., Suurmeijer, A. J.H., Zijlstra, F.
(2009). Incidence and clinical consequences of distal embolization on the coronary angiogram after percutaneous coronary intervention for ST-elevation myocardial infarction. Eur Heart J
30: 908-915
[Abstract][Full Text]
Andreotti, F., Rio, T., Lavorgna, A.
(2009). Body fat and cardiovascular risk: understanding the obesity paradox. Eur Heart J
30: 752-754
[Full Text]
Angiolillo, D. J.
(2009). Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions. Diabetes Care
32: 531-540
[Full Text]
Veverka, A., Hammer, J. M.
(2009). Prasugrel: A New Thienopyridine Inhibitor. Journal of Pharmacy Practice
22: 158-165
[Abstract]
Previous
